LBF20208PG01: Difference between revisions
No edit summary |
No edit summary |
||
| Line 11: | Line 11: | ||
|Chemical Synthesis= | |Chemical Synthesis= | ||
|Metabolism= | |Metabolism= | ||
|Biological Activity= | |Biological Activity= delta 12-PGD2 is catalyzed to delta 12-PGJ2, which has antimitotic and carcinogenic activities.[[Reference:Kato_T:Fukushima_M:Kurozumi_S:Noyori_R:,Cancer Res.,1986,46,3538|{{RelationTable/GetFirstAuthor|Reference:Kato_T:Fukushima_M:Kurozumi_S:Noyori_R:,Cancer Res.,1986,46,3538}}]][[Reference:Fukushima_M:,Eicosanoids,1990,3,189|{{RelationTable/GetFirstAuthor|Reference:Fukushima_M:,Eicosanoids,1990,3,189}}]] | ||
}} | }} | ||
{{Lipid/Footer}} | {{Lipid/Footer}} | ||
Revision as of 14:00, 19 February 2010
| LipidBank Top (トップ) |
Fatty acid (脂肪酸) |
Glycerolipid (グリセロ脂質) |
Sphingolipid (スフィンゴ脂質) |
Journals (雑誌一覧) |
How to edit (ページの書き方) |
| IDs and Links | |
|---|---|
| LipidBank | XPR1771 |
| LipidMaps | LMFA03010101 |
| CAS | |
| KEGG | {{{KEGG}}} |
| KNApSAcK | {{{KNApSAcK}}} |
| mol | LBF20208PG01 |
| δ12-Prostaglandin D2 | |
|---|---|
| |
| Structural Information | |
| 9α,15S-dihydroxy-11-oxo-prosta-5Z,12E-dien-1-oic acid | |
| |
| Formula | C20H32O5 |
| Exact Mass | 352.224974134 |
| Average Mass | 352.46508 |
| SMILES | C(CC[C@H](O)CC=C([C@H]1CC=CCCCC(O)=O)C(C[C@@H]1O)=O)CC |
| Physicochemical Information | |
| delta 12-PGD2 is catalyzed to delta 12-PGJ2, which has antimitotic and carcinogenic activities. Kato_T et al. Fukushima_M | |
| Spectral Information | |
| Mass Spectra | |
| UV Spectra | |
| IR Spectra | |
| NMR Spectra | |
| Other Spectra | |
| Chromatograms | |
| Reported Metabolites, References | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
